Avandia has more bad news: new report finds increased Risks
.jpg)
Avandia, a popular diabetes drug, has just been dealt another strike. A new report from the FDA on Wednesday, finds that patients who take Avandia, face an increased risk of heart attacks over those who take Actos, a similar drug. According to a recent New York Times article, one review in the study included the following statement: "Patients with heart disease and those taking insulin should not take Avandia".
Avandia increases the risks of heart attacks by as much as 40 percent in most diabetes patients. In those taking insulin or nitrates, the risks are higher, according to the drug agency’s analysis. Most diabetics die of heart disease. This news is unsettling, given that the drug was created to save lives, not help cause greater risks.
The FDA is stepping up and diligently trying to ensure the safety of Avandia patients. After the harsh but necessary criticism from Iowa Republican Senator Charles E. Grassley. Mr. Grassley said. “If F.D.A. leaders are asleep at the switch, it’s a dereliction of duty. But if they’re knowingly suppressing information about risks to public safety, then it’s morally corrupt.” We need more lawmakers to stand up and hold agencies in charge with protecting the public accountable. This should be a bi-partisan issue. It affects everyone.
Unfortunately, this news does not bode well for the drug maker, Glaxo Smith Kline, since the drug is billion dollar producer for the company. Last year Avandia had sales over $3.4 billion. Upon news of this new report, the shares of stock fell $1.40, closing at $51.23. I am sure the company executives and shareholders are nervous. If the full report that comes out on Monday, and shows more risks for Avandia patients, the drug could be in more danger. All eyes are on Avandia and the FDA report that comes out on Monday. Should GSK be nervous? Is there really a reason for this alarm? Time will tell if GSK will hit a base hit or a sacrificed fly and score a run with this billion dollar drug? I don't really see how they can hit a home run with this one. The other side seems to have scored a few good runs, with these new findings. Time will tell... Stay tuned....
Click Here to read more on Avandia from the New York Times article
